Anti- Cancer Drug Volasertib Achieves Exemplary Results in Phase II Study

Anti- Cancer Drug Volasertib Achieves Exemplary Results in Phase II Study

volasertibBoehringer Ingelheim recently shared exciting Phase II results from their anti-cancer breakthrough drug Volasertib. Patients enrolled in this landmark study, revealed July 8, 2014, had acute myeloid leukemia, or AML, and were considered to have unresectable cases. The study encompassed an elderly patient population, with every participant being over the age of 65. Results have been declared unusually positive, with survival rates rivaling similar midstage study results of standard chemotherapy. Patients with AML who received a combination of Volasertib and low dose chemotherapy experienced a median overall survival rate of 8 months, in comparison to the patients who were dosed with standard best in care chemotherapy alone. The patients who were administered chemotherapy without Volasertib had a median overall survival rate of 5.2 months. Additionally, the event-free survival rate was 5.6 months for the patient arm who were given both Volasertib and chemotherapy, over twice as long as the rate of patients who were dosed with chemotherapy only, which was 2.3 months of event free survival.

Volasertib is an effective inhibitor of the polo-like kinase which in turn spurs cancer cell death. Acute myeloid leukemia typically affects the elderly population, so Phase II study results of this formidable drug are encouraging, especially for patients who cannot tolerate large amounts of chemotherapy as their only treatment option. A Phase III study of Volasertib is currently underway, with 660 patients suffering from acute myeloid leukemia. The Phase III study will be a multicenter, double-blind trial which is on target to conclude in 2016.

On April 17, 2014 Volasertib was granted Orphan Drug Designation for acute myeloid leukemia by both the European Commission and the FDA. This designation offered hope to the patients inflicted with AML, which is a rare but aggressive type of bone marrow and blood cancer. This virulent disease primarily affects people over the age of 60 and is the cause of approximately one third of adult leukemias in the Western World. Volasertib offers a treatment option for patients with AML who cannot tolerate standard chemotherapy or need the adjunctive use of another anti-cancer agent.

LGM Pharma is a provider of Volasertib, CAS # 755038-65-4, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service